Aprea Therapeutics, Inc. Insider Trading for March 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Aprea Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Aprea Therapeutics, Inc. for March 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 2021 | APRE | Aprea Therapeutics ... | Korbel Gregory Alan | Chief Business Offi ... | Grant | A | 0.00 | 15,000 | 0 | 25,500 | 10.5 K to 25.5 K (+142.86 %) |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Attar Eyal C. | SVP, Chief Medical ... | Option Exercise | A | 6.00 | 143,000 | 858,000 | 143,000 | |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Attar Eyal C. | SVP, Chief Medical ... | Grant | A | 0.00 | 75,000 | 0 | 108,000 | 33 K to 108 K (+227.27 %) |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Attar Eyal C. | SVP, Chief Medical ... | Grant | A | 0.00 | 33,000 | 0 | 33,000 | 0 to 33 K |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Wessels Gregory S. | SVP, Chief Commerci ... | Option Exercise | A | 6.00 | 66,000 | 396,000 | 66,000 | |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Wessels Gregory S. | SVP, Chief Commerci ... | Grant | A | 0.00 | 16,000 | 0 | 16,000 | 0 to 16 K |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Abrahmsen Lars B. | SVP, Chief Scientif ... | Option Exercise | A | 6.00 | 82,000 | 492,000 | 82,000 | |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Abrahmsen Lars B. | SVP, Chief Scientif ... | Grant | A | 0.00 | 19,000 | 0 | 19,000 | 0 to 19 K |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | SCHADE CHRISTIAN S | Chairman & CEO | Option Exercise | A | 6.00 | 329,000 | 1,974,000 | 329,000 | |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | SCHADE CHRISTIAN S | Chairman & CEO | Grant | A | 0.00 | 88,500 | 0 | 176,660 | 88.2 K to 176.7 K (+100.39 %) |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | SCHADE CHRISTIAN S | Chairman & CEO | Grant | A | 0.00 | 77,000 | 0 | 77,160 | 160 to 77.2 K (+48,125.00 %) |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Coiante Scott M | SVP, Chief Financia ... | Option Exercise | A | 6.00 | 143,000 | 858,000 | 143,000 | |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Coiante Scott M | SVP, Chief Financia ... | Grant | A | 0.00 | 63,500 | 0 | 99,000 | 35.5 K to 99 K (+178.87 %) |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Coiante Scott M | SVP, Chief Financia ... | Grant | A | 0.00 | 33,000 | 0 | 35,500 | 2.5 K to 35.5 K (+1,320.00 %) |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Korbel Gregory Alan | VP of Business Dev' ... | Option Exercise | A | 6.00 | 41,100 | 246,600 | 41,100 | |
| Mar 01 2021 | APRE | Aprea Therapeutics ... | Korbel Gregory Alan | VP of Business Dev' ... | Grant | A | 0.00 | 10,000 | 0 | 10,500 | 500 to 10.5 K (+2,000.00 %) |